USFDA grants orphan drug and pediatric exclusivities for Cresemba for aspergillosis and mucormycosis in children

CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications

Biomanufacturing and Bio-foundry will drive India’s future bioeconomy: Dr. Jitendra Singh

India has reached to nearly 6,000 bio-startups from 50 in the past 10 years

Venus Remedies awarded its first incentive of Rs.7.50 crore under PLl scheme

The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics

18% of India's population needs assistive care, says former DGHS

Health Minister Mandaviya inaugurates 27 greenfield bulk drug park, 13 medical device manufacturing plants

PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30

Biocon Biologics secures US market entry date for Bmab 1200

The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA

TechInvention Lifecare breaks ground of its GCMC

The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy

New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions with food allergies

The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies

Orchid Pharma's 'Exblifep' receives USFDA approval

Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA

Jupiter Life Line Hospitals acquires land in Bibvewadi on lease